Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
All products are for laboratory research use only and are not intended for human consumption
Novo completes $16.5bn takeover of Catalent
The evidence supporting GLP-1 medications for weight loss and metabolic health is robust
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
In this episode: Survodutide obesity and liver fat reduction data Mazdutide Phase 3 obesity and diabetes results UBT251 triple agonist weight loss data Berobenatide (MET-097) long-acting GLP-1 updates CagriSema diabetes and obesity trial results Zenagamtide (Amycretin) injectable and oral development Petrelintide amylin agonist info Future GLP-1, GIP, glucagon, and amylin therapies The future of obesity medicine is no longer just about who produces the most weight loss
Some people linked these changes to weight loss, improved body image, better metabolic health, and mental well-being, while others suggested age or underlying health conditions may also play a role
US$ 29.57
US$ 26.23
US$ 25.41
US$ 28.89
US$ 21.96
US$ 23.58
